Study calls for better surveillance to prevent spread of viral hepatitis in WHO European Region

Many countries in the World Health Organization (WHO) European Region are facing limitations in conducting chronic viral hepatitis disease surveillance, assessing the burden of disease and measuring the impact of interventions, according to results revealed today at The International Liver Congress™ 2015.

The study highlights that less than one-third (27%) of WHO European Member States have national strategies in place that contain a surveillance component. Furthermore, only 64% have a national surveillance system for chronic hepatitis B and 61% for chronic hepatitis C.

The study also reveals the main areas in which governments would like the WHO's support:

  • Development of national plans for viral hepatitis prevention and control (39%)
  • Estimation of the national burden of viral hepatitis (34%)
  • Surveillance (23%)

The results were obtained by analysing the responses to surveillance-related questions in the WHO Global Hepatitis Policy Survey. In total, 44 out of 53 (83%) of the WHO European Member States responded to the survey.

The study demonstrates a clear need for better disease surveillance and improvements in the development of national strategies to help prevent and control the spread of viral hepatitis in the WHO European region.

Source: European Association for the Study of the Liver

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Ipsen's elafibranor recommended for use in patients with rare liver disease